Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Common Equity (2016 - 2025)

Iradimed (IRMD) has disclosed Common Equity for 13 consecutive years, with $94.6 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 8.98% to $94.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $94.6 million through Dec 2025, up 8.98% year-over-year, with the annual reading at $94.6 million for FY2025, 8.98% up from the prior year.
  • Common Equity for Q4 2025 was $94.6 million at Iradimed, down from $98.4 million in the prior quarter.
  • The five-year high for Common Equity was $98.4 million in Q3 2025, with the low at $62.5 million in Q1 2022.
  • Average Common Equity over 5 years is $76.1 million, with a median of $72.9 million recorded in 2021.
  • The sharpest move saw Common Equity dropped 3.06% in 2023, then rose 21.56% in 2024.
  • Over 5 years, Common Equity stood at $72.2 million in 2021, then increased by 2.08% to $73.7 million in 2022, then decreased by 3.06% to $71.4 million in 2023, then increased by 21.56% to $86.8 million in 2024, then rose by 8.98% to $94.6 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $94.6 million, $98.4 million, and $94.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.